Array ( [0] => {{Short description|Indian multinational pharmaceutical company}} [1] => {{Use dmy dates|date=January 2016}} [2] => {{Infobox company [3] => | name = Cipla Limited [4] => | logo = Cipla logo.svg [5] => | logo_size = 250px [6] => | trading_name = Cipla [7] => | former_name = Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984) [8] => | type = [[Public company|Public]] [9] => | traded_as = {{BSE|500087}}
{{NSE|CIPLA}}
[[NIFTY 50|NSE NIFTY 50 Constituent]] [10] => | founder = [[Khwaja Abdul Hamied]] [11] => | area_served = Worldwide [12] => | key_people = {{Unbulleted_list|[[Yusuf Hamied|Y. K. Hamied]]
{{small|([[Chairperson]])}}|Umang Vohra
{{small|([[Chief executive officer|Chief Executive Officer]])}}}} [13] => | ISIN = {{ISIN|sl=n|pl=y|INE059A01026}} [14] => | industry = [[Pharmaceuticals]] [15] => | products = {{hlist|[[Medication|Pharmaceutical drugs]]| [[generic drug]]s| [[antiviral drug]]s| [[over-the-counter drug]]s| [[vaccine]]s| [[Medical diagnosis|diagnostics]]| [[contact lens]]es| [[Veterinary medicine|animal health]]| [[dietary supplements]]|[[protein supplement]]s }} [16] => | revenue = {{Increase}} {{INRConvert|22753|c}} (FY23){{cite news |last1=Jaiswar |first1=Pooja Sitaram |title=Cipla Q4 results: Consolidated PAT at ₹526 cr, declares dividend |url=https://www.livemint.com/market/stock-market-news/cipla-q4-results-consolidated-pat-at-rs-526-cr-healthy-growth-in-india-and-us-drives-revenue-key-highlights-here-11683885367430.html |access-date=14 July 2023 |work=Mint |date=12 May 2023 |language=en}} [17] => | operating_income = {{Increase}} {{INRConvert|5027|c}} (FY23) [18] => | net_income = {{Increase}} {{INRConvert|2802|c}} (FY23) [19] => | assets = {{Decrease}} {{INRConvert|23662.56|c}}{{Cite web|title=Cipla Consolidated Balance Sheet, Cipla Financial Statement & Accounts|url=https://www.moneycontrol.com/financials/cipla/consolidated-balance-sheetVI/C|access-date=2020-07-28|website=www.moneycontrol.com|language=en}} [20] => | assets_year = 2020 [21] => | equity = {{Increase}} {{INRConvert|15763.00|c}} [22] => | equity_year = 2020 [23] => | num_employees = 22,036{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/Business_Responsibility_Report_2013_14.pdf |title=Business Responsibility Report 2013-14 |publisher=Cipla |date=15 July 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150317170629/http://www.cipla.com/CiplaSite/Media/PDF/Business_Responsibility_Report_2013_14.pdf |archive-date=17 March 2015 |url-status=dead }} [24] => | parent = [25] => | subsid = Invagen Pharmaceuticals [26] => | homepage = [http://www.cipla.com www.cipla.com] [27] => | footnotes = [28] => | foundation = {{Start date and age|1935||p=y}} [29] => | location = [[Mumbai]], [[Maharashtra]], India [30] => }} [31] => '''Cipla Limited''' (stylized as '''Cipla''') is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai]]. Cipla primarily focuses on developing medication to treat [[respiratory disease]], [[cardiovascular disease]], [[arthritis]], [[diabetes]], [[Depression (mood)|depression]], and various other medical conditions.{{Cite web |title=Know 10 largest Pharmaceutical Companies in India |url=https://www.edudwar.com/top-pharma-companies-in-india/ |access-date=2023-07-28 |website=Edu Dwar}} Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in [[India]].{{cite news |title=Cipla betting big on digitisation and emerging segments |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-betting-big-on-digitisation-and-emerging-segments/articleshow/93406373.cms |access-date=6 December 2022 |work=The Economic Times}}{{cite news |title=Cipla betting big on digitisation and emerging segments |url=https://www.financialexpress.com/healthcare/cipla-betting-big-on-digitisation-and-emerging-segments/2620470/ |access-date=6 December 2022 |work=Financial Express |language=en}} [32] => [33] => ==History == [34] => Cipla was founded in [[Mumbai]] in 1935 by [[Khwaja Abdul Hamied]] as the '''Chemical, Industrial & Pharmaceutical Laboratories'''.{{cite web |url=http://www.cipla.com/Home/About-Us/History.aspx |title=About us - History |publisher=Cipla Limited |access-date=3 November 2014 |archive-url=https://web.archive.org/web/20151027060707/http://www.cipla.com/Home/About-Us/History.aspx |archive-date=27 October 2015 |url-status=dead }}{{cite web |url=http://economictimes.indiatimes.com/cipla-ltd/infocompanyhistory/companyid-13917.cms |title=Company History - Cipla Ltd. |publisher=Economic Times |access-date=3 November 2013}} [35] => In July 1984, the name of the company was changed to 'Cipla'. [36] => [37] => Upon Hamied's death in 1972, his son [[Yusuf Hamied]], a Cambridge-educated chemist, took over the company. [38] => [39] => In 1995, Cipla launched [[Deferiprone]], the world's first oral iron chelator. [40] => [41] => In 1999, Cipla joined the [[Indian Pharmaceutical Alliance]] as a founding member in an effort to promote the development of generic drugs in India.{{Cite news |last=Dec 22 |first=PTI |date=2022-12-22 |title=Indian pharma sector set for 'volume to value leadership' journey in 2023 |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-set-for-volume-to-value-leadership-journey-in-2023/articleshow/96407749.cms |access-date=2023-08-05 |issn=0013-0389}}{{Cite web |title=Introducing IPA- Indian Pharmaceutical Alliance |url=https://www.ipa-india.org/about-ipa/introduction/ |access-date=2023-08-05 |website=IPA, Indian Pharmaceutical Alliance}} During the [[HIV/AIDS|AIDS]] epidemic in the early 2000s, Hamied reverse-engineered a three-drug [[antiretroviral]] medication that was sold for about $12,000 per year to create a cheaper version that sold for $304 per year.{{Cite news |date=2023-08-05 |title=Epic saga of Cipla: How a swadeshi Robin Hood took on Big Pharma of the West |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/epic-saga-of-cipla-how-a-swadeshi-robin-hood-took-on-big-pharma-of-the-west/articleshow/102440967.cms?from=mdr |access-date=2023-08-05 |issn=0013-0389}} This drug was sold to African charities and governments. It is estimated that "at one time, as much as 40 percent of the AIDS patients in poor countries took Cipla drugs". [42] => [43] => During the avian flu pandemic in 2006, Cipla was able to reverse-engineer the drug Tamiflu and sell it for significantly lower prices. [44] => [45] => In 2013 Cipla acquired the [[South Africa|South African]] company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary.{{cite news|last1=Jawani|first1=Lohit|title=Cipla completes acquisition of South Africa's Cipla Medpro|url=http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|work=VC Circle|date=16 July 2013|access-date=8 September 2016|archive-url=https://web.archive.org/web/20160315164809/http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|archive-date=15 March 2016|url-status=dead}}{{cite web|title=Delists from JSE|url=http://www.bdlive.co.za/business/healthcare/2013/07/16/cipla-medpro-delists-from-jse-as-cipla-deal-is-finalised|publisher=Business Day Live|access-date=13 July 2013|date=2013}} At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company. The company had been founded in 2002 under the name Enaleni Pharmaceuticals Ltd.{{cite web|title=Enaleni Pharmaceuticals Limited Prospectus 2005|url=http://globaldocuments.morningstar.com/documentlibrary/document/e00037afcc0c3668.msdoc/original|publisher=Morningstar|access-date=8 September 2016}} In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company;{{cite web|last1=Avafia|first1=Tenu|last2=Berger|first2=Jonathan|last3=Hartzenberg|first3=Trudi|title=The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries|publisher=WHO|url=http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|archive-url=https://web.archive.org/web/20140123042922/http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|url-status=dead|archive-date=23 January 2014|date=2006}} in 2008, it changed its name to Cipla-Medpro.{{cite web|last1=Kahn|first1=Tamar|title=South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro|url=http://allafrica.com/stories/200809100609.html|publisher=All Africa|date=10 September 2008}} In September 2023, it was announced Cipla South Africa had acquired the [[Midrand]]-headquartered healthcare products manufacturer, Actor Pharma.{{Cite web |last=Priyan |first=Vishnu |date=2023-09-05 |title=Cipla to bolster OTC portfolio with acquisition of Actor Pharma |url=https://www.pharmaceutical-technology.com/news/cipla-acquisition-actor-pharma/ |access-date=2023-09-05 |website=Pharmaceutical Technology |language=en-US}} [46] => [47] => In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.{{Cite journal |last=JARVIS |first=LISA |title=Mylan Will Buy Most of Matrix |date=2006-09-04 |url=http://dx.doi.org/10.1021/cen-v084n036.p008 |journal=Chemical & Engineering News Archive |volume=84 |issue=36 |pages=8 |doi=10.1021/cen-v084n036.p008 |issn=0009-2347}} [48] => [49] => In 2019 Cipla entered [[digital therapeutics]] by partnering with Wellthy Therapeutics in [[India]] and Brandmed in [[South Africa]].{{Cite web |date=n.d. |title=Cipla's History |url=https://www.cipla.com/about-us/our-history |access-date=2022-05-16 |website=Cipla South Africa |language=en-US}} [50] => [51] => In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore. {{Cite news|url=https://www.business-standard.com/companies/news/cipla-to-acquire-ivia-beaute-s-cosmetics-personal-care-biz-for-rs-130-cr-124041600197_1.html|title=Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr|newspaper = Business Standard India|date=16 April 2024|agency = Press Trust of India}} [52] => [53] => ==Products and services== [54] => Cipla sells [[active pharmaceutical ingredients]] to other manufacturers as well as pharmaceutical and personal care products,{{cite web |url=http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |archive-url=https://archive.today/20131106234625/http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |url-status=dead |archive-date=6 November 2013 |title=cipla ltd (CIPLA:Natl India) |publisher=Business Week |access-date=7 November 2013 }} including the anti-depressant [[escitalopram oxalate]], [[lamivudine]], and [[fluticasone propionate]].{{cite web |url=https://www.cipla.com/sites/default/files/Annual-Report-FY-2022-23.pdf |title=Annual Report FY 2022-23 |publisher=Cipla |date=15 July 2014 |access-date=October 11, 2023 |archive-url=https://web.archive.org/web/20231011194716/https://www.cipla.com/sites/default/files/Annual-Report-FY-2022-23.pdf |archive-date=2023-10-11 |url-status=live |website=Cipla.com}} Cipla is the world's largest manufacturer of [[antiretroviral drugs]].{{cite press release |url=http://www.prnewswire.com/news-releases/aids-healthcare-foundation-campaign-challenges-cipla-over-drug-pricing-in-india-profit-at-what-cost-aids-drugs-for-all-57993227.html |title=AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India |publisher=PR Newswire |date=8 August 2007 |access-date=4 November 2013}} [55] => [56] => In July 2020, the company announced the introduction of [[Gilead Sciences]]' [[Remdesivir]] under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and [[DCGI]] approval for "restricted emergency use" in [[COVID-19]] treatment of patients in critical condition.{{cite news |date=21 June 2020 |title=India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug |language=en |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-india-remdesivir/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-idUSKBN23S0EO}}{{cite news |title=Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir |url=https://www.financialexpress.com/lifestyle/health/cipla-launches-remdesivir-claims-it-is-inexpensive/2018015/ |work=The Financial Express |date=9 July 2020}}{{cite news |title=Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt |url=https://www.businesstoday.in/current/corporate/coronavirus-drug-cipla-ramps-up-production-of-covid-19-antiviral-remdesivir/story/409758.html |work=businesstoday.in}} [57] => [58] => ==Operations== [59] => [60] => Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.{{cite web|url=http://www.cipla.com/en/corporate-information/at-a-glance.html|title=Corporate Information: At a Glance|publisher=Cipla|access-date=6 July 2019|archive-url=https://web.archive.org/web/20160912104850/http://www.cipla.com/en/corporate-information/at-a-glance.html|archive-date=12 September 2016|url-status=dead}}{{cite news |url=http://www.business-standard.com/article/news-cm/cipla-in-the-pink-of-health-113092500515_1.html |title=Cipla in the pink of health |newspaper=Business Standard |date=25 September 2013 |access-date=5 November 2013}} Exports accounted for 48% {{INRConvert|4948|c|lk=|year=2013}} of its revenue for the 2013–14 fiscal year.{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |title=Annual Report 2013-14 |publisher=Cipla |date=22 August 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150122062022/http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |archive-date=22 January 2015 |url-status=dead }} Cipla spent {{INR}}517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities. The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply. [61] => [62] => During the FY 2013–14, the company incurred {{INRConvert|1285|c|lk=|year=2014}} on employee benefit expenses. [63] => [64] => According to Cipla's 2022-23 annual report, the company had over 25,000 employees, out of which 14.3% were women. [65] => [66] => == Listings and shareholding== [67] => [68] => The equity shares of Cipla are listed on the [[Bombay Stock Exchange]],{{cite web |url=http://www.bseindia.com/stock-share-price/cipla-ltd/cipla/500087/ |title=Cipla Limited |website=BSEindia.com |access-date=2 November 2013}} where it is a constituent of the [[BSE SENSEX]] index,{{cite web |url=http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |title=Scripwise Weightages in S&P BSE SENSEX |publisher=BSE India |access-date=2 November 2013 |archive-url=https://web.archive.org/web/20151201094728/http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |archive-date=1 December 2015 |url-status=dead }} and the [[National Stock Exchange of India]],{{cite web |url=http://www.nseindia.com/live_market/dynaContent/live_watch/get_quote/GetQuote.jsp?symbol=CIPLA |title=NTPC Limited |publisher=NSE India |access-date=2 November 2013}} where it is a constituent of the [[CNX Nifty]].{{cite web |url=http://www.nseindia.com/content/indices/ind_niftylist.csv |title=Download List of CNX Nifty stocks (.csv) |publisher=NSE India |access-date=2 November 2013}} Its [[Global depository receipt|Global Depository Receipts]] (GDRs) are listed on the [[Luxembourg Stock Exchange]]. [69] => [70] => As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. [[SBI Mutual Fund]], [[Life Insurance Corporation of India|LIC]] etc. are the largest non-promoter shareholders in the Company.{{Cite web |title=StockEdge |url=https://web.stockedge.com/share/cipla/5128?section=shareholders |access-date=2023-01-25 |website=web.stockedge.com}} In January 2024, Samina Hamied resigned from her position as the Executive Vice Chairperson of Cipla. She continued to serve the company as a non-executive director subject to rotational retirement. [71] => [72] => {| class="wikitable" [73] => |- [74] => ! Shareholders (as on 31-December-2022) !! Shareholding{{Cite web |title=Latest CIPLA Shareholding Pattern |url=https://www.equitymaster.com/stock-research/shareholding-pattern/CIPL/CIPLA-Shareholding-Pattern |access-date=2023-01-25 |website=Equitymaster}} [75] => |- [76] => | Promoter Group|| 33.61% [77] => |- [78] => | Mutual funds|| 14.09% [79] => |- [80] => |Financial Institution/Banks/Insurance [81] => |4.96% [82] => |- [83] => | Foreign Institutional Investors (FII)|| 28.39% [84] => |- [85] => |Corporate Bodies [86] => |0.53% [87] => |- [88] => | Individuals|| 14.72% [89] => |- [90] => |NRIs/OCBs [91] => |0.88% [92] => |- [93] => |ADRs/GDRs [94] => |NIL [95] => |- [96] => | Others|| 2.82% [97] => |- [98] => [99] => | '''Total'''||'''100.00%''' [100] => |} [101] => [102] => ==Awards and recognitions== [103] => * In 1980, Cipla won Chemexcil Award for Excellence for exports.{{cite web |title=Company Profile - Cipla Limited |url=http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Cipla-Ltd/500087 |access-date=3 November 2013 |website=IndiaInfoline.com}} [104] => * In 2006, Cipla won Dun & Bradstreet American Express Corporate Awards.{{cite web |date=10 September 2006 |title=Pharmaceutical sector award |url=http://www.dnb.co.in/top500/photogal5.html |url-status=dead |archive-url=https://archive.today/20131104104713/http://www.dnb.co.in/top500/photogal5.html |archive-date=4 November 2013 |access-date=3 November 2013 |publisher=Dun & Bradstreet}} [105] => * In 2007, [[Forbes Asia|Forbes]] included Cipla in the 200 'Best under a billion' list of best small Asian companies.{{cite news |date=17 November 2005 |title=Asian Paints, Cipla in Forbes list |newspaper=Economic Times |url=http://articles.economictimes.indiatimes.com/2005-11-17/news/27509362_1_forbes-list-asia-pacific-list-asian-paints |access-date=3 November 2013}} [106] => * In 2012, Cipla received the Thomson Reuters India Innovation Award.[http://pharmabiz.com/NewsDetails.aspx?aid=72283&sid=1 DBT, Cipla get Thomson Reuters India innovation awards] [107] => * In 2015, Cipla stood third in the [[India's Most Reputed Brands]] (Pharmaceutical) list,"[https://economictimes.indiatimes.com/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list]". ''The Economic Times''. timesofindia.com. 17 August 2016. Retrieved 6 July 2019. in a study conducted by BlueBytes,{{cite web |url=http://www.bluebytes.info/ |title=Home |website=bluebytes.info}} a Media Analytics firm in association with TRA Research,{{cite web |url=http://www.trustadvisory.info/ |title=Home |website=trustadvisory.info}} a brand insights organization (both part of the Comniscient Group). [108] => [109] => ==Criticism== [110] => [111] => ===Emergency contraception=== [112] => In August 2007, Cipla launched an [[emergency contraception]] drug "i-pill" sold [[over the counter]],{{cite news |url=http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |archive-url=https://web.archive.org/web/20150205102533/http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |url-status=dead |archive-date=5 February 2015 |title=Cipla rises on morning-after pill |newspaper=Hindustan Times |date=5 October 2007 |access-date=3 November 2013}}. The drugged sparked controversy as it was available without prescription and contained a large amount of API per dosage.{{cite news |url=http://healthcare.financialexpress.com/200710/market09.shtml |title=Cipla Launches i-pill |newspaper=Financial Express |access-date=3 November 2013}}{{cite news |url=http://www.financialexpress.com/news/-ipill-by-cipla-draws-criticism-from-experts/232556 |title='i-pill' by Cipla draws criticism from experts |newspaper=Financial Express |date=27 October 2007 |access-date=3 November 2013}} [113] => [114] => ===Generic drugs=== [115] => In the late 1960s, Cipla began manufacturing a new, patented drug, [[propranolol]], without the permission of the drug's patent holder, [[Imperial Chemical Industries]]; a protest was filed with the Indian government. The CEO of Cipla pressured the [[First Indira Gandhi ministry|government of Indira Gandhi]] to change India's [[patent laws]] to eliminate patents that directly covered drugs, and instead to allow only patents that covered [[chemical synthesis|methods to make drugs]]{{cite news |url=https://www.wired.com/wired/archive/14.12/indiadrug.html |title=The Treasure of Mumbai |newspaper=Wired Magazine |date=December 2006 |access-date=4 November 2013}} so that Cipla could produce low-priced generic drugs. Since then, Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries.{{cite news |url=https://www.nationalheraldindia.com/india/heart-warming-story-of-the-hamieds-who-set-up-cipla-and-have-been-saving-lives |title= Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives |newspaper=National Herald |date=April 2020 |access-date=12 April 2020}} The changes made led to criticism of both India's patent laws and Cipla.{{cite web|url=http://biohealthinvestor.com/2007/01/indian-generic-drug-maker-targets-sad-americans.html |title=Indian Generic Drug Maker Targets Sad Americans |website=biohealthinvestor.com |date=3 January 2007 |access-date=4 November 2013}} India reinstated patents on drugs in 2005. [116] => [117] => ==See also== [118] => {{Portal|Companies}} [119] => * [[Pharmaceutical industry in India]] [120] => * [[Generic drug]] [121] => * [[List of pharmaceutical companies]] [122] => [123] => ==References== [124] => {{reflist}} [125] => [126] => ==External links== [127] => * {{Official website|http://www.cipla.com}} [128] => [129] => {{Nifty 200 companies}} [130] => {{CNX Nifty companies}} [131] => {{Authority control}} [132] => [133] => [[Category:Biotechnology companies of India]] [134] => [[Category:Pharmaceutical companies of India]] [135] => [[Category:Pharmaceutical companies established in 1935]] [136] => [[Category:NIFTY 50]] [137] => [[Category:Biopharmaceutical companies]] [138] => [[Category:Indian brands]] [139] => [[Category:Indian companies established in 1935]] [140] => [[Category:Companies listed on the National Stock Exchange of India]] [141] => [[Category:Companies listed on the Bombay Stock Exchange]] [] => )
good wiki

Cipla

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. It is one of the largest pharmaceutical companies in India and its products are sold in over 150 countries worldwide.

More about us

About

It is one of the largest pharmaceutical companies in India and its products are sold in over 150 countries worldwide. The company specializes in the development, manufacturing, and marketing of generic medicines, as well as a range of pharmaceuticals and active pharmaceutical ingredients. Cipla was founded in 1935 by Khwaja Abdul Hamied as The Chemical, Industrial & Pharmaceutical Laboratories. It initially focused on manufacturing and distributing a wide range of affordable medicines to combat diseases such as tuberculosis and malaria. Over the years, Cipla has expanded its product portfolio to include drugs for various therapeutic areas, including respiratory, cardiovascular, oncology, and HIV/AIDS. Cipla has been at the forefront of several important healthcare initiatives in India and globally. In the 1960s, the company played a significant role in the production and distribution of the tuberculosis drug, isoniazid, which helped India become the first country to achieve mass treatment of the disease. Cipla has also been a pioneer in making antiretroviral drugs more accessible and affordable in the treatment of HIV/AIDS in developing countries. The company has a strong focus on research and development, and has established state-of-the-art research facilities in India and South Africa. Cipla has collaborated with multiple international partners to develop innovative drugs and biosimilars. It has also entered into licensing agreements to manufacture and distribute drugs in emerging markets. Cipla has received several accolades for its contributions to the healthcare sector, including the prestigious Thomson Reuters India Innovation Award and the prestigious Chemistry and Allied Sciences category, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Award for non-profit work in public health, and the UN Climate Action Award for its environmental sustainability efforts. As of 2020, Cipla is listed on the Bombay Stock Exchange and the National Stock Exchange of India, and its shares are also traded on international exchanges. The company continues to expand its global presence and is committed to improving access to affordable medicines worldwide.

Expert Team

Vivamus eget neque lacus. Pellentesque egauris ex.

Award winning agency

Lorem ipsum, dolor sit amet consectetur elitorceat .

10 Year Exp.

Pellen tesque eget, mauris lorem iupsum neque lacus.

You might be interested in

Antiretroviral

Diabetes

Diabetes is a chronic metabolic disorder characterized by high levels of glucose (sugar) in the blood.

HIV/AIDS

HIV/AIDS is a global pandemic caused by the human immunodeficiency virus (HIV).

Pharmaceutical

Pharmaceuticals